Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein

Infect Immun. 2006 May;74(5):2706-16. doi: 10.1128/IAI.74.5.2706-2716.2006.

Abstract

Heterologous prime-boost immunization with DNA and various recombinant poxviruses encoding malaria antigens is capable of inducing strong cell-mediated immune responses and partial protection in human sporozoite challenges. Here we report a series of trials assessing recombinant fowlpox virus and modified vaccinia virus Ankara encoding the Plasmodium falciparum circumsporozoite protein in various prime-boost combinations, doses, and application routes. For the first time, these vaccines were administered intramuscularly and at doses of up to 5 x 10(8) PFU. Vaccines containing this antigen proved safe and induced modest immune responses but showed no evidence of efficacy in a sporozoite challenge.

MeSH terms

  • Adult
  • Animals
  • Antibodies, Protozoan / blood
  • Clinical Trials as Topic
  • Glycosylphosphatidylinositols / physiology
  • Humans
  • Immunization, Secondary
  • Interferon-gamma / biosynthesis
  • Malaria Vaccines / adverse effects
  • Malaria Vaccines / immunology*
  • Parasitemia / prevention & control
  • Plasmodium falciparum / immunology*
  • Poxviridae / genetics
  • Protozoan Proteins / immunology*
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / immunology*
  • Vaccinia virus / genetics

Substances

  • Antibodies, Protozoan
  • Glycosylphosphatidylinositols
  • Malaria Vaccines
  • Protozoan Proteins
  • Vaccines, Synthetic
  • circumsporozoite protein, Protozoan
  • plasmanylinositol glycan
  • Interferon-gamma